NASDAQ:IRMDIradimed Stock Price, Forecast & News

Iradimed's stock was trading at $22.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IRMD shares have decreased by 3.7% and is now trading at $21.67. View which stocks have been most impacted by Coronavirus.

Iradimed is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Iradimed.

Iradimed Corp (NASDAQ:IRMD) released its earnings results on Thursday, April, 30th. The medical equipment provider reported $0.18 EPS for the quarter, topping the Zacks' consensus estimate of $0.15 by $0.03. The medical equipment provider had revenue of $8.68 million for the quarter, compared to analysts' expectations of $8.72 million. Iradimed had a return on equity of 17.99% and a net margin of 24.65%. View Iradimed's earnings history.

Iradimed updated its first quarter 2020 IntraDay earnings guidance on Tuesday, April, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $8.6-8.7 million, compared to the consensus revenue estimate of $10.61 million.

0 brokerages have issued twelve-month price targets for Iradimed's shares. Their forecasts range from $30.00 to $30.00. On average, they anticipate Iradimed's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 38.4% from the stock's current price. View analysts' price targets for Iradimed.

News articles about IRMD stock have trended extremely negative on Monday, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Iradimed earned a news sentiment score of -4.5 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutIradimed.

Iradimed saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 468,000 shares, an increase of 7.6% from the April 15th total of 434,900 shares. Based on an average daily volume of 48,100 shares, the days-to-cover ratio is currently 9.7 days. Currently, 7.9% of the shares of the stock are short sold. View Iradimed's Current Options Chain.

Some companies that are related to Iradimed include Cerus (CERS), Tactile Systems Technology (TCMD), OraSure Technologies (OSUR), Cryolife (CRY), Orthopediatrics (KIDS), Orthofix Medical (OFIX), GenMark Diagnostics (GNMK), Vapotherm (VAPO), Co-Diagnostics (CODX), SurModics (SRDX), LeMaitre Vascular (LMAT), SI-Bone (SIBN), Antares Pharma (ATRS), Anika Therapeutics (ANIK) and Repro-Med Systems (REPR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Micron Technology (MU), Paypal (PYPL), Crispr Therapeutics (CRSP), IntriCon (IIN), Mastercard (MA), NovaBay Pharmaceuticals (NBY) and NovaBay Pharmaceuticals (NBY).

Iradimed trades on the NASDAQ under the ticker symbol "IRMD."

Iradimed's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.02%), Russell Investments Group Ltd. (2.57%), Nine Ten Capital Management LLC (2.30%), Ranger Investment Management L.P. (1.95%), Soleus Capital Management L.P. (1.95%) and RK Capital Management LLC (1.75%). Company insiders that own Iradimed stock include Anthony Vuoto, Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen and Steven M Nardi. View institutional ownership trends for Iradimed.

IRMD stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Squarepoint Ops LLC, JPMorgan Chase & Co., RK Capital Management LLC, Ranger Investment Management L.P., AQR Capital Management LLC, Cadence Capital Management LLC, and BlackRock Inc.. Company insiders that have sold Iradimed company stock in the last year include Anthony Vuoto, Brent Johnson, Louis S Waldman, Monty K Allen, and Steven M Nardi. View insider buying and selling activity for Iradimed.

IRMD stock was purchased by a variety of institutional investors in the last quarter, including Nine Ten Capital Management LLC, Soleus Capital Management L.P., Russell Investments Group Ltd., Morgan Stanley, Globeflex Capital L P, Rice Hall James & Associates LLC, Alliancebernstein L.P., and Acadian Asset Management LLC. View insider buying and selling activity for Iradimed.

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IRMD stock can currently be purchased for approximately $21.67.

Iradimed has a market capitalization of $261.12 million and generates $38.52 million in revenue each year. The medical equipment provider earns $9.63 million in net income (profit) each year or $0.78 on an earnings per share basis. Iradimed employs 95 workers across the globe.

The official website for Iradimed is www.iradimed.com.

Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]